A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials
Clinical Trial News Wednesday, August 29th, 2012ctj.sagepub.com: 7/18/12
Background Most Phase II clinical trials utilize a single primary end point to determine the promise of a regimen for future study. However, many disorders manifest themselves in complex ways. For example, migraine headaches can cause pain, auras, photophobia, and emesis. Investigators may believe that a drug is effective at reducing migraine pain and the severity of emesis during an attack. Nevertheless, they could still be interested in proceeding with the development of the drug if it is effective against only one of these symptoms. Such a study would be a candidate for a clinical trial with co-primary end points. Read more
